Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2024-05-03 | 2024-07-26 | 227065 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2018-11-16 | 2019-01-17 | 67034 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-05-26 | 2023-06-16 | 193212 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2024-04-12 | 2024-07-26 | 225005 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-04-08 | 2022-06-12 | 158373 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-07-22 | 2022-09-01 | 165335 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2022-10-21 | 2023-01-06 | 172347 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-07 | 2023-12-22 | 203843 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-09-15 | 2023-12-22 | 204417 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212377 |
APO-TERBINAFINE | 250MG | TABLET | Resolved | 2019-02-13 | 2020-08-10 | 75632 |
APO-TERIFLUNOMIDE | 14MG | TABLET | Resolved | 2023-10-27 | 2024-01-12 | 208385 |
APO-TERIPARATIDE INJECTION | 250MCG | SOLUTION | Resolved | 2025-03-20 | 2025-05-02 | 253081 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2017-09-07 | 2017-11-22 | 21209 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2018-01-31 | 2018-05-16 | 37749 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2020-06-24 | 2020-10-13 | 118781 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2021-08-16 | 2021-09-07 | 144209 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2024-06-06 | 2024-09-20 | 229764 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2024-10-04 | 2025-03-21 | 239370 |
APO-TETRABENAZINE | 25MG | TABLET | Resolved | 2021-04-05 | 2021-05-03 | 136814 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |